Quantinno Capital Management LP Has $3.53 Million Holdings in LivaNova PLC $LIVN

Quantinno Capital Management LP grew its holdings in LivaNova PLC (NASDAQ:LIVN) by 263.8% during the first quarter, Holdings Channel.com reports. The firm owned 55,562 shares of the company’s stock after buying an additional 40,289 shares during the period. Quantinno Capital Management LP’s holdings in LivaNova were worth $3,532,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Hantz Financial Services Inc. grew its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming acquired a new position in LivaNova in the 2nd quarter valued at approximately $31,000. EverSource Wealth Advisors LLC lifted its position in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new stake in shares of LivaNova during the 3rd quarter valued at $36,000. Finally, Covestor Ltd boosted its stake in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LIVN. KeyCorp upped their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of LivaNova in a research report on Tuesday. Mizuho boosted their target price on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Needham & Company LLC upped their target price on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Freedom Capital raised LivaNova to a “hold” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $83.50.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is owned by insiders.

LivaNova Stock Performance

LIVN stock opened at $76.22 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $4.20 billion, a price-to-earnings ratio of 22.55 and a beta of 0.86. LivaNova PLC has a 12 month low of $48.57 and a 12 month high of $85.76. The firm has a 50 day moving average of $79.64 and a two-hundred day moving average of $70.75.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same quarter last year, the firm earned $1.05 EPS. LivaNova’s revenue for the quarter was up 10.8% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. As a group, equities analysts anticipate that LivaNova PLC will post 3.75 EPS for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.